Ambelvist

Clinical

Trials by Indication[1]

Contrast Enhancement in Magnetic Resonance Imaging2 trials

A Multicenter, Randomized, Prospective Double-blind, Cross-over Phase 3 Study to Evaluate the Efficacy and Safety of 0.04 mmol Gd/kg Body Weight of Gadoquatrane for MRI in Adults With Known or Suspected Pathology of Any Body Region (Except CNS), Compared to 0.1 mmol Gd/kg Approved Macrocyclic Gadolinium-based Contrast Agents (GBCAs)

Completed·Bayer·Phase 3·NCT05915728·410 enrolled

A Multicenter, Prospective, Open-label Study to Evaluate the Pharmacokinetics and Safety of Gadoquatrane in Pediatric Participants (From Birth to <18 Years) Undergoing Contrast-enhanced Magnetic Resonance Imaging (CE-MRI)

Completed·Bayer·Phase 3·NCT05915026·105 enrolled

Single Dose1 trial

A Study to Learn More About the Safety and the Blood Level of BAY1747846 Given as Injection Into the Vein at Increasing Single Doses in Chinese Healthy Male Participants

Completed·Bayer·Phase 1·NCT06135181·24 enrolled

Magnetic Resonance Imaging (MRI)1 trial

Study to Find the Appropriate Dose of a New Gadolinium-based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions

Completed·Bayer·Phase 2·NCT04307186·57 enrolled

Contrast Agent1 trial

A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems

Completed·Bayer·Phase 3·NCT05915702·303 enrolled

Regulatory

FDA Approval Timeline[3]

Details

Drug Info

Patent Landscape[4]

Related News